805.93

0.52% -4.3777

Regeneron Pharmaceuticals Inc (REGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt REGN? Forum Prognose

Schlusskurs vom Vortag:

$810.31

Offen:

$803.83

24-Stunden-Volumen:

222.80K

Relative Volume:

0.28

Marktkapitalisierung:

$82.94B

Einnahmen:

$14.92B

Nettoeinkommen (Verlust:

$4.42B

KGV:

19.64

EPS:

41.0422

Netto-Cashflow:

$3.79B

1W Leistung:

-5.39%

1M Leistung:

+2.77%

6M Leistung:

+3.13%

1J Leistung:

+44.84%

1-Tages-Spanne:

$796.73

$808.63

1-Wochen-Bereich:

$796.73

$859.34

52-Wochen-Spanne:

$541.00

$859.34

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Firmenname

Regeneron Pharmaceuticals Inc

Sektor

Healthcare (1086)

Branche

Biotechnology (606)

Telefon

(914) 847-7000

Adresse

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Mitarbeiter

15,410

Twitter

@regeneron

Nächster Verdiensttermin

2026-10-27

Neueste SEC-Einreichungen

REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REGN Regeneron Pharmaceuticals Inc	805.56	83.43B	14.92B	4.42B	3.79B	41.04
VRTX Vertex Pharmaceuticals Inc	520.55	134.06B	12.34B	4.34B	3.71B	16.87
ARGX Argen X Se Adr	1,006.43	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.79	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.68	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-31	Fortgesetzt	Piper Sandler	Overweight
2026-03-06	Eingeleitet	Barclays	Overweight
2026-01-07	Hochstufung	BofA Securities	Underperform → Buy
2025-12-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Eingeleitet	HSBC Securities	Buy
2025-11-24	Fortgesetzt	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Perform
2025-08-14	Eingeleitet	Rothschild & Co Redburn	Buy
2025-06-30	Herabstufung	Argus	Buy → Hold
2025-05-30	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-05-14	Hochstufung	Citigroup	Neutral → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-02-05	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-01-16	Herabstufung	UBS	Buy → Neutral
2024-12-10	Fortgesetzt	BofA Securities	Underperform
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Neutral
2024-09-24	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-03-12	Eingeleitet	Bernstein	Outperform
2024-01-12	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-03	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-08-21	Hochstufung	Canaccord Genuity	Hold → Buy
2023-08-21	Bestätigt	Oppenheimer	Perform
2023-06-28	Herabstufung	Canaccord Genuity	Buy → Hold
2023-03-27	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-24	Hochstufung	Jefferies	Hold → Buy
2023-03-23	Hochstufung	Raymond James	Underperform → Mkt Perform
2023-01-30	Hochstufung	Cowen	Market Perform → Outperform
2023-01-20	Hochstufung	JP Morgan	Neutral → Overweight
2022-10-26	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-10-17	Herabstufung	Evercore ISI	Outperform → In-line
2022-09-09	Hochstufung	Jefferies	Underperform → Hold
2022-09-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2022-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2022-01-03	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-12-15	Herabstufung	Bernstein	Outperform → Mkt Perform
2021-12-09	Fortgesetzt	Wells Fargo	Overweight
2021-12-07	Fortgesetzt	Cowen	Market Perform
2021-12-06	Eingeleitet	Goldman	Buy
2021-11-19	Fortgesetzt	BMO Capital Markets	Outperform
2021-11-05	Herabstufung	The Benchmark Company	Buy → Hold
2021-06-29	Eingeleitet	H.C. Wainwright	Buy
2021-01-25	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Hochstufung	The Benchmark Company	Hold → Buy
2021-01-08	Hochstufung	Citigroup	Neutral → Buy
2020-10-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2020-07-09	Hochstufung	SunTrust	Hold → Buy
2020-05-26	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-04-28	Herabstufung	Citigroup	Buy → Neutral
2020-04-17	Hochstufung	The Benchmark Company	Hold → Buy
2020-04-08	Eingeleitet	The Benchmark Company	Hold
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-02-26	Hochstufung	Canaccord Genuity	Hold → Buy
2020-02-26	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-02-25	Hochstufung	Jefferies	Hold → Buy
2020-02-11	Hochstufung	Argus	Hold → Buy
2019-12-24	Eingeleitet	Raymond James	Mkt Perform
2019-12-16	Herabstufung	Evercore ISI	Outperform → In-line
2019-12-13	Hochstufung	Credit Suisse	Neutral → Outperform
2019-11-12	Eingeleitet	SunTrust	Hold
2019-11-07	Hochstufung	Citigroup	Neutral → Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Neutral
2019-09-23	Hochstufung	Guggenheim	Neutral → Buy

Alle ansehen

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

10:51 AM

Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN) - Yahoo Finance

10:51 AM

10:22 AM

Regeneron at Wells Fargo healthcare conference: growth broadens By Investing.com - Investing.com UK

10:22 AM

10:09 AM

Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026REGN - PR Newswire

10:09 AM

10:05 AM

Transcript : Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08 - marketscreener.com

10:05 AM

08:18 AM

Why is Regeneron Pharmaceuticals (NASDAQ:REGN) drawing investor attention today? - Kalkine Media

08:18 AM

Sep 08, 2026

(REGN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com

Sep 08, 2026

REGN 6-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire

Sep 08, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - GlobeNewswire Inc.

Sep 08, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN - GlobeNewswire Inc.

Sep 08, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Sep 08, 2026

Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock - Yahoo Finance

Sep 08, 2026

Did Libtayo Recall Just Shift Regeneron's (REGN) Investment Narrative? - simplywall.st

Sep 08, 2026

REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire

Sep 08, 2026

REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Sep 08, 2026

Regeneron stock holds firm after strong Q2 2026 results - AD HOC NEWS

Sep 08, 2026

MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 DeadlineRGRD Law - marketscreener.com

Sep 08, 2026

3 Reasons to Avoid REGN and 1 Stock to Buy Instead - The Globe and Mail

Sep 08, 2026

Sep 07, 2026

1 WEEK REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile

Sep 07, 2026

REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Re - natlawreview.com

Sep 07, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Sep 07, 2026

Regeneron stock holds near lofty levels as class action risk emerges - AD HOC NEWS

Sep 07, 2026

Sep 06, 2026

REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile

Sep 06, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire

Sep 06, 2026

Regeneron stock slips on a $85.2 billion market value - AD HOC NEWS

Sep 06, 2026

Sep 05, 2026